FDA is alerting health care professionals, oncology clinical investigators and patients about the risks associated with the investigational use of Venclexta (venetoclax) for the treatment of patients with multiple myeloma based on data from a clinical trial. Venclexta is not approved for the treatment of multiple myeloma.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
